Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), Kyverna Therapeutics, Inc. (KYTX) and Monopar Therapeutics Inc (MNPR)

Tipranks - Tipranks - Tue Mar 31, 5:36AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Illumina (ILMN), Kyverna Therapeutics, Inc. (KYTX) and Monopar Therapeutics Inc (MNPR).

End of Quarter Sale - 50% Off TipRanks

Illumina (ILMN)

In a report released today, Daniel Brennan from TD Cowen maintained a Hold rating on Illumina, with a price target of $117.67. The company’s shares closed last Friday at $117.67.

According to TipRanks.com, Brennan is a 5-star analyst with an average return of 14.6% and a 44.9% success rate. Brennan covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

Currently, the analyst consensus on Illumina is a Hold with an average price target of $128.35, which is a 4.3% upside from current levels. In a report issued on March 23, Canaccord Genuity also maintained a Hold rating on the stock with a $150.00 price target.

See today’s best-performing stocks on TipRanks >>

Kyverna Therapeutics, Inc. (KYTX)

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Kyverna Therapeutics, Inc., with a price target of $20.00. The company’s shares closed last Friday at $7.80.

According to TipRanks.com, Kapoor is a 4-star analyst with an average return of 8.5% and a 38.7% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Lexeo Therapeutics, Inc., BioMarin Pharmaceutical, and Crispr Therapeutics AG. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kyverna Therapeutics, Inc. with a $26.50 average price target, a 230.0% upside from current levels. In a report issued on March 27, William Blair also maintained a Buy rating on the stock.

Monopar Therapeutics Inc (MNPR)

In a report issued on March 27, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Monopar Therapeutics Inc, with a price target of $105.00. The company’s shares closed last Friday at $54.10, close to its 52-week high of $54.30.

According to TipRanks.com, Maldonado is a 5-star analyst with an average return of 45.1% and a 50.7% success rate. Maldonado covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Zentalis Pharmaceuticals, and NovaBridge Biosciences. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Monopar Therapeutics Inc with a $112.71 average price target, representing a 107.2% upside. In a report released today, Barclays also maintained a Buy rating on the stock with a $125.00 price target.

Read More on ILMN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).